Iwamiya, Metcela’s co-CEO, spoke at ACCJ x LINK-J event: “The Front Line of the Regenerative Medicine Business: Practical Application of Cell Medicine” | Metcela Inc.

In this fifth session of our Technology Series, the ACCJ-Kansai Business Programs Committee is pleased to welcome Dr. Takahiro Iwamiya, co-founder of Metcela Inc. The number of patients with heart failure is on the rise worldwide. Providing new treatment opportunities for this disease is an urgent issue, as there is concern that—due to the so-called heart failure pandemic—the number of cases and patients, as well as medical expenses, will increase.

Against this backdrop, Metcela is developing a combination regenerative medicine product: 1) VCAM1-positive cardiac fibroblasts (VCF) which assist with myocardial regeneration, and 2) a catheter for cell administration.In this session, Dr. Iwamiya will discuss:

• Metcela’s science and technology, as well as the actual situation and trends of regenerative medicine for heart failure
• Observations and failures he has experienced managing Metcela as a founding scientist
• Entrepreneurship as a new career path for scientists
• The future of Metcela and the ideal image of an R&D-type venture